Provided by Integrity Continuing Education, Inc.
Funding for this Independent Medical Education Grant is being provided from Pfizer Inc and Myovant Sciences Ltd.
Hormone-based intervention with androgen deprivation therapy (ADT) has been the cornerstone of treatment for men with advanced prostate cancer (PCa) for decades, since the first gonadotropin-releasing hormone (GnRH) agonist was introduced in 1985. This critical advance remained the standard of care until the approval of the first GnRH antagonist in 2008. The GnRH antagonists, degarelix and oral relugolix, have an immediate onset of action with no associated testosterone surge. Additionally, GnRH antagonists have been associated with fewer adverse cardiovascular events, which prompted some genitourinary oncologists to call for a new standard of care for patients with PCa who have or are at high risk for cardiovascular disease. By participating in this activity, clinicians will gain a better understanding of the current landscape of PCa treatment with an emphasis on the most recent clinical data and approvals.
Rana R. McKay, MD
Associate Professor of Medicine
Co-Leader, Genitourinary Disease Team
Moores Cancer Center
University of California, San Diego
La Jolla, California
Brian I. Rini, MD, FASCO
Professor of Medicine
Chief of Clinical Trials
Vanderbilt Ingram Cancer Center
This educational activity has been designed to meet the needs of urologists, medical oncologists, radiation oncologists, and other clinicians who treat men with advanced prostate cancer, including internal medicine physicians, physician assistants, and nurse practitioners who specialize in genitourinary oncology.
Upon completion of this educational activity, participants should be able to:
There are no fees for participating and receiving CME credit for this activity. During the period of December 15, 2021 through December 15, 2022, participants must:
A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 100%.
Physician Continuing Education
Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Integrity Continuing Education, Inc. designates this other activity for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or firstname.lastname@example.org.
Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.
The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of these CME activities:
Rana R. McKay, MD
Advisory Boards: AstraZeneca, Bayer, Bristol-Myers Squibb, Calithera, Caris Life Sciences, Dendreon, Exelixis, Johnson & Johnson, Merck, Myovant, Sanofi, Sorrento Therapeutics, Tempus
Research (Institution): Bayer, Tempus
Brian I. Rini, MD, FASCO
Consulting Fees: Alkermes, Aravive, Arrowhead Pharmaceuticals, Aveo, Bristol-Myers Squibb, Compugen, Corvus, Eisai, Genentech-Roche, GlaxoSmithKline, Merck, Pfizer, Shinonogi, Surface Oncology, Synthorx, 3DMedicines
Research Funding (Institution): Aravive, Arrowhead Pharmaceuticals, AstraZeneca, Bristol-Myers Squibb, Dragonfly Therapeutics, Exelixis, Genentech-Roche, GlaxoSmithKline, Hoffman-LaRoche, Immunomedics, Incyte, Merck, Mirati Therapeutics, Pfizer, Seattle Genetics, Surface Oncology, Taris
Stock: PTC Therapeutics
The Integrity Continuing Education, Inc. planners and managers have nothing to disclose.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc. you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)
Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe® Flash® Player 10
For optimal performance, the use of Internet Explorer below 8 is not recommended
For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements
The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.